GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects a multi-blockbuster ...

For the past three years, biotechs and pharmas have renamed, rebranded and more in a bid to refresh their corporate appeal. ...

The company’s consolidated profit excluding minority interest dropped to EGP 105.826 million in January-September from EGP 46.728 million a year earlier ...

(Alliance News) - GSK PLC on Thursday said its Blenrep drug has shown overall survival benefits in patients with relapsed or refractory multiple myeloma, the third most common type of blood cancer.

GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...

Major companies like pharma giant GlaxoSmithKline (GSK) have established their largest AI teams in London. The city is a global leader in AI talent, as well as home to leading AI research centres, ...

GSK Pharmaceuticals India focuses on affordable general medicine access amidst premiumisation trend, discussed by managing ...

Bell reported relationships with the Dementia Australia Research Foundation, GlaxoSmithKline Supported Studies Programme, ...

Aytu BioPharma (NASDAQ: AYTU) is a pharmaceutical company focused on commercializing novel therapeutics. The Company’s ...

GSK added Ojjaara to its portfolio through the acquisition of Sierra in 2022. Credit: Magda Wygralak via Shutterstock. Health ...

Further boosting the pipeline, mid-stage drugs like Sanofi/Regeneron’s itepekimab, AstraZeneca’s benralizumab, Amgen Inc ...

The bottom half of the list featured Reckitt Benckiser’s Mucinex, AstraZeneca’s Breztri Aerosphere, Otsuka’s Rexulti, ...